<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03996694</url>
  </required_header>
  <id_info>
    <org_study_id>BUP-401</org_study_id>
    <nct_id>NCT03996694</nct_id>
  </id_info>
  <brief_title>Single Dose Crossover Study to Compare the Respiratory Drive After Administration of Belbuca, Oxycodone and Placebo.</brief_title>
  <official_title>A Randomized, Double-Blind, Double Dummy, 6-Period, Placebo-Controlled, Crossover Study to Explore and Compare the Ventilatory Response to Hypercapnia (VRH), of Belbuca, Oxycodone Hydrochloride (HCl) and Placebo in Recreational Opioid Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioDelivery Sciences International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PRA Health Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BioDelivery Sciences International</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore and compare VRH after administration of Belbuca,&#xD;
      Oxycodone HCl and Placebo in recreational opioid users. This is a single-center, double&#xD;
      -blind, double-dummy , placebo-controlled randomized crossover study in up to 18 men and&#xD;
      women self identifying as recreational users. This study will consist of a screening phase,&#xD;
      treatment phase (which includes the Naloxone Challenge test) and follow-up visit.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 23, 2019</start_date>
  <completion_date type="Actual">October 27, 2019</completion_date>
  <primary_completion_date type="Actual">October 27, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Respiratory Drive</measure>
    <time_frame>pre-dose, 0.5, 1, 1.5, 2, 2.5, 3 and 4 hours</time_frame>
    <description>Respiratory drive was evaluated by measuring the Ventilatory Response to Hypercapnia (VRH) through assessment of the maximum decrease (Emax) in minute ventilation (mL/min) after administration of Belbuca, Oxycodone hydrochloride, and placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pupil Diameter</measure>
    <time_frame>pre-dose, 0.5, 1, 1.5, 2, 2.5, 3 and 4 hours</time_frame>
    <description>Pupil diameter will be assessed by pupillometry predose and at multiple timepoints after completion of Belbuca, oxycodone hydrochloride, and placebo dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ratio of Minute Ventilation</measure>
    <time_frame>pre-dose, 0.5, 1, 2, 2.5, 3 and 4 hours</time_frame>
    <description>Change in ratio of maximum decrease (Emax) in minute ventilation (mL/min) over maximum (Emax) end-tidal carbon dioxide (CO2, mmHg) after administration of Belbuca, oxycodone hydrochloride, and placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event (AE) Reporting of Belbuca, Oxycodone Hydrochloride and Placebo for 6 Periods.</measure>
    <time_frame>44 days</time_frame>
    <description>Number of Participants with indicated Adverse Event (AE) in subjects receiving Belbuca, oxycodone hydrochloride, and placebo for 6 periods.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Respiratory Depression</condition>
  <arm_group>
    <arm_group_label>Treatment A: Belbuca 300 µg and oral placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects treated with Belbuca 300 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: Belbuca 600 µg and oral placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects treated with Belbuca 600 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C: Belbuca 900 µg and oral placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects treated with Belbuca 900 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D: Oxycodone 30 mg and buccal placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects treated with Oxycodone 30 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment E: Oxycodone 60 mg and buccal placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects treated with Oxycodone 60 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment F: Oral Placebo and buccal placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects treated with oral placebo and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belbuca 300 µg</intervention_name>
    <description>Belbuca 300 µg buccal film</description>
    <arm_group_label>Treatment A: Belbuca 300 µg and oral placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belbuca 600 µg</intervention_name>
    <description>Belbuca 600 µg buccal film</description>
    <arm_group_label>Treatment B: Belbuca 600 µg and oral placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belbuca 900 µg</intervention_name>
    <description>Belbuca 900 µg buccal film</description>
    <arm_group_label>Treatment C: Belbuca 900 µg and oral placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone 30 mg</intervention_name>
    <description>Oxycodone 30 mg capsule</description>
    <arm_group_label>Treatment D: Oxycodone 30 mg and buccal placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone 60 mg</intervention_name>
    <description>Oxycodone 60 mg capsule</description>
    <arm_group_label>Treatment E: Oxycodone 60 mg and buccal placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo buccal film and oral placebo</description>
    <arm_group_label>Treatment F: Oral Placebo and buccal placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects 18 to 55 years of age, inclusive.&#xD;
&#xD;
          2. Subjects are in good health as indicated by medical history, PE, vital signs, oxygen&#xD;
             saturation, clinical laboratory tests, and 12-lead ECG. A status of good health will&#xD;
             be defined by the absence of evidence of any clinically significant, active or chronic&#xD;
             disease based on these assessments, in the opinion of the investigator.&#xD;
&#xD;
          3. Subjects with a body mass index (BMI) of 18.0 to 33.0 kg/m2, inclusive, and body&#xD;
             weight greater than 50 kg, inclusive.&#xD;
&#xD;
          4. Subject is able to speak, read, and understand English and voluntarily provide written&#xD;
             informed consent to participate in the study.&#xD;
&#xD;
          5. Subjects have healthy oral mucosa as determined by examination at screening and&#xD;
             admission to the clinical facility.&#xD;
&#xD;
          6. Subject must be a recreational opioid user who is not currently dependent on opioids&#xD;
             (based on self-reported DSM-5 criteria and a Clinical Opiate Withdrawal Scale [COWS]&#xD;
             score ≤5 on the Naloxone Challenge) but has experience in the use of opioids for&#xD;
             non-therapeutic purposes (ie, for psychoactive effects) on at least 10 occasions&#xD;
             within the last year and at least once in the 12 weeks prior to the screening visit.&#xD;
&#xD;
          7. Subject demonstrates adequate VRH at screening during VRH assessment, defined as a&#xD;
             minimum increase in ETCO2 of 10 mmHg and an increase in minute ventilation appropriate&#xD;
             per investigator's discretion.&#xD;
&#xD;
          8. Ability and willingness to abstain from alcohol-, caffeine-, and xanthine-containing&#xD;
             beverages or food (eg, coffee, tea, cola, chocolate, energy drinks) as well as poppy&#xD;
             seeds from 48 hours (2 days) prior to each admission to the clinical facility until&#xD;
             study discharge (including clinic furloughs).&#xD;
&#xD;
          9. Female subjects who are non-pregnant, non-lactating, and either postmenopausal for at&#xD;
             least 1 year or surgically sterile for at least 3 months, or, if of childbearing&#xD;
             potential, will agree to use adequate contraception from 28 days and/or their last&#xD;
             confirmed menstrual period prior to study enrollment (whichever is longer) until 90&#xD;
             days after the follow-up visit. Male subjects, if not surgically sterilized, must&#xD;
             agree to use adequate contraception and not donate sperm from first admission to the&#xD;
             clinical research center until 90 days after the follow-up visit. Adequate&#xD;
             contraception (for both males and females) is defined as using spermicide with a&#xD;
             single barrier method: diaphragm, cervical cap, or condom. For female participants and&#xD;
             female partners of male participants, being surgically sterilized or using hormonal&#xD;
             contraception or an intrauterine device is also acceptable. Also, total abstinence, in&#xD;
             accordance with the lifestyle of the subject, is acceptable.&#xD;
&#xD;
         10. For female subjects: a negative pregnancy test at screening and Day -1 of each&#xD;
             treatment period.&#xD;
&#xD;
         11. Postmenopausal females: defined as 12 months with no menses prior to screening and a&#xD;
             serum follicle stimulating hormone (FSH) &gt;40 IU/L at screening.&#xD;
&#xD;
         12. All prescribed medications, over-the-counter (OTC) medications, dietary supplements or&#xD;
             herbal supplements (eg, St. John's Wort extract) must have been stopped at least 14&#xD;
             days prior to the first admission to the clinical research center. An exception is&#xD;
             made for acetaminophen, which is allowed up to admission to the clinical research&#xD;
             center. An exception is also made for hormonal contraceptives, which may be used&#xD;
             throughout the study. Antiemetics may be allowed after the 4-hour VRH assessments&#xD;
             while confined in the clinical research unit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Employee of PRA or the Sponsor.&#xD;
&#xD;
          2. Women who are pregnant, lactating, or planning to attempt to become pregnant during&#xD;
             this study or within 90 days after the follow-up visit.&#xD;
&#xD;
          3. Male subjects with female partners who are pregnant, lactating, or planning to attempt&#xD;
             to become pregnant during this study or within 90 days after the follow-up visit.&#xD;
&#xD;
          4. Has received study medication in another clinical trial within 30 days prior to the&#xD;
             first dose of study medication.&#xD;
&#xD;
          5. Having any disease that, in the opinion of the investigator, poses an unacceptable&#xD;
             risk to the subjects.&#xD;
&#xD;
          6. History of drug allergy diagnosed by a physician. Confirmatory circumstances would&#xD;
             include treatment with epinephrine or an Emergency Department.&#xD;
&#xD;
          7. Subjects who have smoked on a daily basis within 30 days prior to the first dose of&#xD;
             study medication. Occasional nicotine use in the form of cigarettes, cigars, or vape&#xD;
             pen is allowable (defined as less than half a pack of cigarettes [10 cigarettes],&#xD;
             equivalent vaping [100 puffs], or no more than 2 cigars per week). Nicotine&#xD;
             replacement therapies (ie, patches and/or gum) may be used without restriction.&#xD;
&#xD;
          8. Routine or chronic use of more than 3 grams of acetaminophen daily.&#xD;
&#xD;
          9. Strenuous activity and contact sports within 48 hours (2 days) prior to first&#xD;
             admission to the clinical facility and for the duration of the study.&#xD;
&#xD;
         10. History of donation of more than 450 mL of blood within 60 days prior to dosing in the&#xD;
             clinical research center or planned donation before 30 days has elapsed since intake&#xD;
             of study drug.&#xD;
&#xD;
         11. Plasma or platelet donation within 7 days of first dose administration and throughout&#xD;
             the entire study.&#xD;
&#xD;
         12. History of or presence of alcohol dependence. This includes subjects who have never&#xD;
             been to a drug rehabilitation program. Alcohol consumption will be prohibited 48 hours&#xD;
             prior to admission to the clinical facility and throughout the entire study until&#xD;
             discharge.&#xD;
&#xD;
         13. Positive screening test for hepatitis B surface antigen (HBsAg), anti-hepatitis C&#xD;
             virus (HCV) antibodies, or antihuman immunodeficiency virus (HIV)-1 and -2 antibodies.&#xD;
&#xD;
         14. History or presence of clinically significant cardiovascular, pulmonary, hepatic,&#xD;
             renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,&#xD;
             neurologic, oncologic, or psychiatric disease, or any other condition, which, in the&#xD;
             opinion of the investigator, would jeopardize the safety of the subject or the&#xD;
             validity of the study results.&#xD;
&#xD;
         15. Has any condition in which an opioid is contraindicated (eg, significant respiratory&#xD;
             depression, acute or severe bronchial asthma or hypercarbia, or has or is suspected of&#xD;
             having paralytic ileus).&#xD;
&#xD;
         16. Have a history of chronic obstructive pulmonary disease or any other lung disease (eg,&#xD;
             asthma, bronchitis, obstructive sleep apnea, exercise-induced asthma) that would cause&#xD;
             CO2 retention.&#xD;
&#xD;
         17. Has participated in (within the last 5 years), is currently participating in, or is&#xD;
             seeking treatment for substance-related disorders (excluding nicotine and caffeine).&#xD;
&#xD;
         18. A positive result for drugs of abuse (amphetamines, methamphetamines, barbiturates,&#xD;
             benzodiazepines, cocaine, and opioids, including oxycodone) at screening is acceptable&#xD;
             as long as the urine drug screen is negative for these drugs at admission to the&#xD;
             clinical facility. A positive test for THC is not exclusionary at screening or at&#xD;
             admission to the clinical facility. If a subject has a positive urine drug screen&#xD;
             (except THC) upon admission to the clinic (V3-V7) the subject will be dismissed from&#xD;
             the clinic and will be allowed to return at a later date (+14 days) to participate in&#xD;
             the missed treatment period. A subject may only test positive once (except THC) and be&#xD;
             allowed to return.&#xD;
&#xD;
         19. Has oral sores, mucositis, or inflammation in oral cavity at screening and check-in.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynn Webster</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRA Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA-EDS</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 21, 2019</study_first_submitted>
  <study_first_submitted_qc>June 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2019</study_first_posted>
  <results_first_submitted>September 8, 2020</results_first_submitted>
  <results_first_submitted_qc>January 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 5, 2021</results_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Pain</keyword>
  <keyword>Ventilatory Response to Hypercapnia (VRH)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT03996694/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT03996694/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ABCDEF</title>
          <description>Participants received a single dose of Treatment A, followed by a 7-day washout, then crossed over to the sequential treatments in the same manner</description>
        </group>
        <group group_id="P2">
          <title>BCDEFA</title>
          <description>Participants received a single dose of Treatment A, followed by a 7-day washout, then crossed over to the sequential treatments in the same manner</description>
        </group>
        <group group_id="P3">
          <title>CDEFAB</title>
          <description>Participants received a single dose of Treatment A, followed by a 7-day washout, then crossed over to the sequential treatments in the same manner</description>
        </group>
        <group group_id="P4">
          <title>DEFABC</title>
          <description>Participants received a single dose of Treatment A, followed by a 7-day washout, then crossed over to the sequential treatments in the same manner</description>
        </group>
        <group group_id="P5">
          <title>EFABCD</title>
          <description>Participants received a single dose of Treatment A, followed by a 7-day washout, then crossed over to the sequential treatments in the same manner</description>
        </group>
        <group group_id="P6">
          <title>FABCDE</title>
          <description>Participants received a single dose of Treatment A, followed by a 7-day washout, then crossed over to the sequential treatments in the same manner</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>First Washout (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>positive urine drug screen</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Washout (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Washout (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Fourth Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Fourth Washout (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Fifth Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Fifth Washout (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Sixth Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Arms</title>
          <description>Subject disposition for all arms</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.1" spread="4.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Respiratory Drive</title>
        <description>Respiratory drive was evaluated by measuring the Ventilatory Response to Hypercapnia (VRH) through assessment of the maximum decrease (Emax) in minute ventilation (mL/min) after administration of Belbuca, Oxycodone hydrochloride, and placebo.</description>
        <time_frame>pre-dose, 0.5, 1, 1.5, 2, 2.5, 3 and 4 hours</time_frame>
        <population>The Completer Set consisted of all randomized subjects who completed all 6 treatment periods in the treatment phase with a valid VRH minute ventilation Emax measurement in each completed treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Belbuca 300 µg and Oral Placebo</title>
            <description>Subjects treated with Belbuca 300 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Belbuca 300 µg: Belbuca 300 µg buccal film</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: Belbuca 600 µg and Oral Placebo</title>
            <description>Subjects treated with Belbuca 600 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Belbuca 600 µg: Belbuca 600 µg buccal film</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Belbuca 900 µg and Oral Placebo</title>
            <description>Subjects treated with Belbuca 900 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Belbuca 900 µg: Belbuca 900 µg buccal film</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: Oxycodone 30 mg and Buccal Placebo</title>
            <description>Subjects treated with Oxycodone 30 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Oxycodone 30 mg: Oxycodone 30 mg capsule</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: Oxycodone 60 mg and Buccal Placebo</title>
            <description>Subjects treated with Oxycodone 60 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Oxycodone 60 mg: Oxycodone 60 mg capsule</description>
          </group>
          <group group_id="O6">
            <title>Treatment F: Oral Placebo and Buccal Placebo</title>
            <description>Subjects treated with oral placebo and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Placebo: placebo buccal film and oral placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Drive</title>
          <description>Respiratory drive was evaluated by measuring the Ventilatory Response to Hypercapnia (VRH) through assessment of the maximum decrease (Emax) in minute ventilation (mL/min) after administration of Belbuca, Oxycodone hydrochloride, and placebo.</description>
          <population>The Completer Set consisted of all randomized subjects who completed all 6 treatment periods in the treatment phase with a valid VRH minute ventilation Emax measurement in each completed treatment period.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23957.34" spread="5554.061"/>
                    <measurement group_id="O2" value="22460.95" spread="8957.064"/>
                    <measurement group_id="O3" value="23626.79" spread="5025.767"/>
                    <measurement group_id="O4" value="21577.15" spread="806.552"/>
                    <measurement group_id="O5" value="17223.80" spread="4486.557"/>
                    <measurement group_id="O6" value="22645.74" spread="6965.108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pupil Diameter</title>
        <description>Pupil diameter will be assessed by pupillometry predose and at multiple timepoints after completion of Belbuca, oxycodone hydrochloride, and placebo dosing.</description>
        <time_frame>pre-dose, 0.5, 1, 1.5, 2, 2.5, 3 and 4 hours</time_frame>
        <population>The Completer Set consisted of all randomized subjects who completed all 6 treatment periods in the treatment phase with a valid VRH minute ventilation Emax measurement in each completed treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Belbuca 300 µg and Oral Placebo</title>
            <description>Subjects treated with Belbuca 300 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Belbuca 300 µg: Belbuca 300 µg buccal film</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: Belbuca 600 µg and Oral Placebo</title>
            <description>Subjects treated with Belbuca 600 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Belbuca 600 µg: Belbuca 600 µg buccal film</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Belbuca 900 µg and Oral Placebo</title>
            <description>Subjects treated with Belbuca 900 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Belbuca 900 µg: Belbuca 900 µg buccal film</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: Oxycodone 30 mg and Buccal Placebo</title>
            <description>Subjects treated with Oxycodone 30 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Oxycodone 30 mg: Oxycodone 30 mg capsule</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: Oxycodone 60 mg and Buccal Placebo</title>
            <description>Subjects treated with Oxycodone 60 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Oxycodone 60 mg: Oxycodone 60 mg capsule</description>
          </group>
          <group group_id="O6">
            <title>Treatment F: Oral Placebo and Buccal Placebo</title>
            <description>Subjects treated with oral placebo and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Placebo: placebo buccal film and oral placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Pupil Diameter</title>
          <description>Pupil diameter will be assessed by pupillometry predose and at multiple timepoints after completion of Belbuca, oxycodone hydrochloride, and placebo dosing.</description>
          <population>The Completer Set consisted of all randomized subjects who completed all 6 treatment periods in the treatment phase with a valid VRH minute ventilation Emax measurement in each completed treatment period.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.93" spread="0.676"/>
                    <measurement group_id="O2" value="5.11" spread="1.063"/>
                    <measurement group_id="O3" value="4.91" spread="0.564"/>
                    <measurement group_id="O4" value="5.11" spread="0.922"/>
                    <measurement group_id="O5" value="4.82" spread="0.962"/>
                    <measurement group_id="O6" value="4.87" spread="1.150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hours Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.65" spread="0.770"/>
                    <measurement group_id="O2" value="5.00" spread="1.020"/>
                    <measurement group_id="O3" value="4.91" spread="0.667"/>
                    <measurement group_id="O4" value="4.17" spread="1.041"/>
                    <measurement group_id="O5" value="3.48" spread="1.147"/>
                    <measurement group_id="O6" value="4.90" spread="1.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.49" spread="0.774"/>
                    <measurement group_id="O2" value="4.83" spread="0.973"/>
                    <measurement group_id="O3" value="4.32" spread="0.617"/>
                    <measurement group_id="O4" value="3.09" spread="0.741"/>
                    <measurement group_id="O5" value="2.77" spread="0.726"/>
                    <measurement group_id="O6" value="4.71" spread="1.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.42" spread="0.833"/>
                    <measurement group_id="O2" value="4.45" spread="0.838"/>
                    <measurement group_id="O3" value="3.85" spread="0.412"/>
                    <measurement group_id="O4" value="3.16" spread="0.693"/>
                    <measurement group_id="O5" value="2.81" spread="0.798"/>
                    <measurement group_id="O6" value="4.75" spread="1.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.89" spread="0.703"/>
                    <measurement group_id="O2" value="3.80" spread="0.698"/>
                    <measurement group_id="O3" value="3.27" spread="0.476"/>
                    <measurement group_id="O4" value="3.17" spread="0.721"/>
                    <measurement group_id="O5" value="2.7" spread="0.633"/>
                    <measurement group_id="O6" value="4.65" spread="0.952"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 hours Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.87" spread="0.736"/>
                    <measurement group_id="O2" value="3.56" spread="0.676"/>
                    <measurement group_id="O3" value="3.15" spread="0.517"/>
                    <measurement group_id="O4" value="3.31" spread="0.688"/>
                    <measurement group_id="O5" value="2.87" spread="0.728"/>
                    <measurement group_id="O6" value="4.89" spread="1.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" spread="0.732"/>
                    <measurement group_id="O2" value="3.31" spread="0.688"/>
                    <measurement group_id="O3" value="2.99" spread="0.548"/>
                    <measurement group_id="O4" value="3.28" spread="0.722"/>
                    <measurement group_id="O5" value="2.82" spread="0.665"/>
                    <measurement group_id="O6" value="4.80" spread="0.963"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.57" spread="0.720"/>
                    <measurement group_id="O2" value="3.25" spread="0.625"/>
                    <measurement group_id="O3" value="2.92" spread="0.653"/>
                    <measurement group_id="O4" value="3.51" spread="0.716"/>
                    <measurement group_id="O5" value="2.90" spread="0.634"/>
                    <measurement group_id="O6" value="4.89" spread="0.903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ratio of Minute Ventilation</title>
        <description>Change in ratio of maximum decrease (Emax) in minute ventilation (mL/min) over maximum (Emax) end-tidal carbon dioxide (CO2, mmHg) after administration of Belbuca, oxycodone hydrochloride, and placebo.</description>
        <time_frame>pre-dose, 0.5, 1, 2, 2.5, 3 and 4 hours</time_frame>
        <population>The Completer Set consisted of all randomized subjects who completed all 6 treatment periods in the treatment phase with a valid VRH minute ventilation Emax measurement in each completed treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Belbuca 300 µg and Oral Placebo</title>
            <description>Subjects treated with Belbuca 300 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Belbuca 300 µg: Belbuca 300 µg buccal film</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: Belbuca 600 µg and Oral Placebo</title>
            <description>Subjects treated with Belbuca 600 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Belbuca 600 µg: Belbuca 600 µg buccal film</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Belbuca 900 µg and Oral Placebo</title>
            <description>Subjects treated with Belbuca 900 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Belbuca 900 µg: Belbuca 900 µg buccal film</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: Oxycodone 30 mg and Buccal Placebo</title>
            <description>Subjects treated with Oxycodone 30 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Oxycodone 30 mg: Oxycodone 30 mg capsule</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: Oxycodone 60 mg and Buccal Placebo</title>
            <description>Subjects treated with Oxycodone 60 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Oxycodone 60 mg: Oxycodone 60 mg capsule</description>
          </group>
          <group group_id="O6">
            <title>Treatment F: Oral Placebo and Buccal Placebo</title>
            <description>Subjects treated with oral placebo and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Placebo: placebo buccal film and oral placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ratio of Minute Ventilation</title>
          <description>Change in ratio of maximum decrease (Emax) in minute ventilation (mL/min) over maximum (Emax) end-tidal carbon dioxide (CO2, mmHg) after administration of Belbuca, oxycodone hydrochloride, and placebo.</description>
          <population>The Completer Set consisted of all randomized subjects who completed all 6 treatment periods in the treatment phase with a valid VRH minute ventilation Emax measurement in each completed treatment period.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="591.74" spread="135.568"/>
                    <measurement group_id="O2" value="536.28" spread="195.123"/>
                    <measurement group_id="O3" value="576.76" spread="115.782"/>
                    <measurement group_id="O4" value="518.81" spread="162.565"/>
                    <measurement group_id="O5" value="411.88" spread="100.259"/>
                    <measurement group_id="O6" value="546.09" spread="179.371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Event (AE) Reporting of Belbuca, Oxycodone Hydrochloride and Placebo for 6 Periods.</title>
        <description>Number of Participants with indicated Adverse Event (AE) in subjects receiving Belbuca, oxycodone hydrochloride, and placebo for 6 periods.</description>
        <time_frame>44 days</time_frame>
        <population>There were N=19 subjects randomized in the BUP-401 study. Of the randomized subjects, N=19 subjects received at least one dose of study medication and were included in the Safety Set, 4 subjects discontinued the study before completing all six treatments in the crossover design.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Belbuca 300 µg and Oral Placebo</title>
            <description>Subjects treated with Belbuca 300 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Belbuca 300 µg: Belbuca 300 µg buccal film</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: Belbuca 600 µg and Oral Placebo</title>
            <description>Subjects treated with Belbuca 600 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Belbuca 600 µg: Belbuca 600 µg buccal film</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Belbuca 900 µg and Oral Placebo</title>
            <description>Subjects treated with Belbuca 900 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Belbuca 900 µg: Belbuca 900 µg buccal film</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: Oxycodone 30 mg and Buccal Placebo</title>
            <description>Subjects treated with Oxycodone 30 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Oxycodone 30 mg: Oxycodone 30 mg capsule</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: Oxycodone 60 mg and Buccal Placebo</title>
            <description>Subjects treated with Oxycodone 60 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Oxycodone 60 mg: Oxycodone 60 mg capsule</description>
          </group>
          <group group_id="O6">
            <title>Treatment F: Oral Placebo and Buccal Placebo</title>
            <description>Subjects treated with oral placebo and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Placebo: placebo buccal film and oral placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event (AE) Reporting of Belbuca, Oxycodone Hydrochloride and Placebo for 6 Periods.</title>
          <description>Number of Participants with indicated Adverse Event (AE) in subjects receiving Belbuca, oxycodone hydrochloride, and placebo for 6 periods.</description>
          <population>There were N=19 subjects randomized in the BUP-401 study. Of the randomized subjects, N=19 subjects received at least one dose of study medication and were included in the Safety Set, 4 subjects discontinued the study before completing all six treatments in the crossover design.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>44 days</time_frame>
      <desc>N=19 subjects received at least one dose of study medication and included in the Safety Set, 4 subjects discontinued:&#xD;
1 subject completed Treatment C - period 1&#xD;
1 subject completed Treatment B-period 1&#xD;
1 subject completed Treatment C-period 1&#xD;
1 subject completed Treatments E, F, and A-periods 1, 2, and 3&#xD;
Of the N=19 subjects in the safety set, N=15 completed all 6 treatments for completers There were N=16 in the Partial Completers Set (subjects who completed at least 2 treatments).</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment A: Belbuca 300 µg and Oral Placebo</title>
          <description>Subjects treated with Belbuca 300 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Belbuca 300 µg: Belbuca 300 µg buccal film</description>
        </group>
        <group group_id="E2">
          <title>Treatment B: Belbuca 600 µg and Oral Placebo</title>
          <description>Subjects treated with Belbuca 600 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Belbuca 600 µg: Belbuca 600 µg buccal film</description>
        </group>
        <group group_id="E3">
          <title>Treatment C: Belbuca 900 µg and Oral Placebo</title>
          <description>Subjects treated with Belbuca 900 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Belbuca 900 µg: Belbuca 900 µg buccal film</description>
        </group>
        <group group_id="E4">
          <title>Treatment D: Oxycodone 30 mg and Buccal Placebo</title>
          <description>Subjects treated with Oxycodone 30 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Oxycodone 30 mg: Oxycodone 30 mg capsule</description>
        </group>
        <group group_id="E5">
          <title>Treatment E: Oxycodone 60 mg and Buccal Placebo</title>
          <description>Subjects treated with Oxycodone 60 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Oxycodone 60 mg: Oxycodone 60 mg capsule</description>
        </group>
        <group group_id="E6">
          <title>Treatment F: Oral Placebo and Buccal Placebo</title>
          <description>Subjects treated with oral placebo and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.&#xD;
Placebo: placebo buccal film and oral placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Rhythm idioventricular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual Impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Feeling of relaxation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Mental Impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Euphoric Mood</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E5" events="9" subjects_affected="9" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Todd Kunkel, PharmD Director, Scientific Communications</name_or_title>
      <organization>BioDelivery Sciences</organization>
      <phone>913-940-1789</phone>
      <email>tkunkel@bdsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

